The 2023 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Overview

2023 RWHAP CLINICAL CONFERENCE Description

The 2023 Ryan White HIV/AIDS Program (RWHAP) CLINICAL CONFERENCE will be held in-person in Portland, Oregon, from Sunday, December 3, to Tuesday, December 5. The RWHAP CLINICAL CONFERENCE will provide state-of-the-art updates on research, care, and treatment issues in the medical management of HIV infection for experienced HIV clinical decision makers.

The 2023 RWHAP CLINICAL CONFERENCE is planned with and supported by the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services (HRSA) and is sponsored and organized by the International Antiviral Society-USA (IAS-USA). This conference is coordinated through the RWHAP AIDS Education and Training Centers (AETC) clinician training network.

Participation of clinical decision makers from RWHAP-funded clinics and programs in this educational activity is an integral part of HRSA’s commitment to improving the care and enriching the lives of individuals with HIV. A mix of lectures, case-based interactive presentations, and small-group workshop breakout sessions will be held during the 3 days of the 2023 RWHAP CLINICAL CONFERENCE.

Who Should Attend

Attendance is exclusively reserved for HIV clinical decision makers, primarily physicians, nurse practitioners, and physician assistants in Ryan White HIV/AIDS Program (RWHAP)-funded clinics and programs (specifically those operating under part A, B, C, and D), who are responsible for direct patient care and the decisions on clinical care and practice carried out at their clinics.

For those clinics that do not have clinical decision makers or do not have one available at the time to participate, the 2023 RWHAP CLINICAL CONFERENCE offers a limited number of registration spots open specifically for pharmacists and registered nurses who play crucial roles in making clinical decisions within their respective RWHAP-funded clinics or programs. Interested pharmacists and registered nurses should register early since these spots are on a first-come basis.

A key element of the CLINICAL CONFERENCE and integral to HRSA’s commitment to supporting clinicians is that participants from RWHAP-funded clinics or programs are expected to provide relevant updates and training to their clinical colleagues who were unable to attend the conference. Comprehensive resources will be made available to facilitate the development of lectures and educational meetings after the conference.

Each RWHAP-funded clinic (whether through Part A, Part B, Part C, Part D, or a combination of any of these) may register up to 3 eligible staff members to attend.

There is no registration fee to attend.

Learning Objectives

The educational objectives for the 2023 RWHAP CLINICAL CONFERENCE are designed and developed based on the identified needs and knowledge gaps of the attendees.

On completion of the 2023 RWHAP CLINICAL CONFERENCE, participants will be able to:

• Describe the new aspects to the Ryan White HIV/AIDS Program
• Identify situations in which the choice of antiretroviral regimen should consider particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Describe the most current data on currently available and investigational new antiretroviral drugs, formulations, and strategies
• Initiate and monitor HIV prevention intervention strategies, including the use of long-acting injectable preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
• Describe the current epidemiology, clinical presentations, and management of the most common sexually transmitted infections (STIs) in adults with HIV infection and in special populations such as adolescents
• Detect and address practitioner and staff burnout
• Describe the current best practices of postnatal HIV care and prevention, including issues around breastfeeding
• Implement key primary care practices
• Describe the implications of bNAbs vaccines for an HIV vaccine
• Detect and manage opioid use disorder in people with HIV
• Provide gender-affirming care to people with HIV
• Address health disparities in disparate populations

Topics

• Day 1: Sunday, December 3, 2023
  • HRSA HAB Updates
  • HIV and immunologic agin
  • Aging and HIV with a focus on cognitive neurologic aspects
  • Addressing mental health in patients with HIV
  • In Case You Missed It; Recent Changes in Guidelines, New Publications, and Updates from Recent Conferences

• • Concurrent Meet-the-Expert Breakout Sessions
    • Ryan White HIV/AIDS Program Listening Session
    • Aging and HIV: Exploring Neurocognitive Aspects
    • Management of Mental Health in Patients with HIV
    • Issues in HIV Primary Care Session 1
    • General Women’s Health Concerns
    • HIV and Immunologic aging

• Day 2: Monday, December 4, 2023
  • HIV vaccines, including bNAbs
  • Diagnosis and management of syphilis in HIV
  • Pregnancy in people with HIV
  • Doxycycline PEP for chlamydia and gonorrhea prevention
  • Antiretroviral Therapy: Cases from the Clinic(ians)
  • Substance use disorder management
  • Drug Interactions between ART and recreational drugs
  • Burnout and resilience among HIV clinicians

• • Concurrent Meet-the-Expert Breakout Sessions
    • Pregnancy in People with HIV
    • Doxycycline PEP: Enhancing Chlamydia and Gonorrhea Prevention Strategies
    • Difficult Cases in Antiretroviral Therapy I
    • Practitioner Burnout and Resilience
    • Challenges in Diagnosis and Management of Syphilis in HIV

• Day 3: Tuesday, December 5, 2023
  • Primary care in HIV with a focus on update on routine immunizations
  • Lipid impact on cardiovascular disease in HIV
  • Future Directions of Investigational Antiretroviral Drugs
  • Case-based presentation on PEP and PrEP

• • Concurrent Meet-the-Expert Breakout Sessions
    • Issues in HIV Primary Care Session 2
    • Lipid Impact on Cardiovascular Disease in HIV
    • Managing Substance Use Disorders
    • Exploring PEP and PrEP for HIV Prevention
    • Drug Interactions Between ART and Recreational Drugs

IAS-USA Accreditation Statement

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 17 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

American Academy of Family Physicians Credits

These activities are eligible for AAFP credit, see final AAFP activity announcement for specific details.

Nursing Credits

These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.

Conference Funding

This conference is funded by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) under grant number U1OHA28686.